Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585560 | 0.82 | PTPN11 (0.48) | BRAFNAMPTPIK3C3ABL1FGFR1 | |
| SCHEMBL23781693 | 0.77 | ALDH1A1 (0.63) | EGLN1ABL1HDAC6ALDH1A1 | |
| SCHEMBL1586122 | 0.76 | CYP2C19 (0.42) | BRAFPIK3C3ABL1CYP2C9CYP2C19 | |
| SCHEMBL27870216 | 0.74 | EGLN1 (0.39) | BRAFEGLN1PIK3C3ABL1FGFR1 | |
| SCHEMBL22777894 | 0.73 | EGLN1 (0.42) | EGLN1ALDH1A1 | |
| SCHEMBL21591503 | 0.72 | GRM5 (0.43) | EGLN1CYP2C9CYP2C19 | |
| SCHEMBL24340235 | 0.72 | ABL1 (0.52) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| SCHEMBL23781611 | 0.72 | HCAR2 (0.43) | EGLN1CYP2C9CYP2C19 | |
| SCHEMBL23781601 | 0.72 | CYP2A6 (0.57) | EGLN1CYP2C9CYP2C19HDAC6 | |
| SCHEMBL503744 | 0.71 | BRAF (0.39) | BRAFPIK3C3ABL1FGFR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | BRAF 504/4885EGLN1 1248/4885NAMPT 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.